Charat Thongprayoon1,2, Wisit Cheungpasitporn1,3, Michael A Mao1, Ankit Sakhuja4, Stephen B Erickson1. 1. Division of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, Rochester, MN, USA. 2. Department of Internal Medicine, Bassett Medical Center, Cooperstown, NY, USA. 3. Division of Nephrology, Department of Medicine, University of Mississippi Medical Center, Jackson, MS, USA. 4. Division of Pulmonary and Critical Care Medicine, Department of Medicine, Mayo Clinic, Rochester, MN, USA.
Abstract
BACKGROUND: The risk of acute kidney injury (AKI) development among hospitalised patients with elevated calcium levels on admission remains unclear. The aim of this study was to assess the risk of AKI in hospitalised patients stratified by various admission serum calcium levels. METHODS: This is a single-centre retrospective study conducted at a tertiary referral hospital. All hospitalised adult patients who had admission calcium levels available between 2009 and 2013 were enrolled. Admission calcium was categorised based on its distribution into six groups (≤7.9, 8.0-8.4, 8.5-8.9, 9.0-9.4, 9.5-9.9, and ≥10.0 mg/dL). The primary outcome was hospital-acquired AKI. Logistic regression analysis was performed to obtain the odds ratio of AKI for various admission calcium strata using calcium levels of 8.0-8.4 mg/dL (lowest incidence of AKI) as the reference group. RESULTS: A total of 12 784 patients were studied. Hospital-acquired AKI occurred in 1779 (13.9%) patients. The incidence of AKI among patients with admission calcium ≤7.9, 8.0-8.4, 8.5-8.9, 9.0-9.4, 9.5-9.9 and ≥10 mg/dL was 14.7%, 11.7%, 11.8%, 14.6%, 15.8% and 17.3%, respectively. After adjusting for potential confounders, admission calcium levels ≤7.9, 9.0-9.4, 9.5-9.9 and ≥10 mg/dL were associated with increased risk of AKI with odds ratios of 1.36 (95%CI 1.08-1.72), 1.29 (95%CI 1.08-1.56), 1.38 (95%CI 1.14-1.68) and 1.51 (95%CI 1.19-1.91), respectively. CONCLUSION: Admission hypocalcaemia and hypercalcaemia are associated with an increased risk for hospital acquired AKI. Patients with admission hypercalcaemia (≥10 mg/dL) carry a 1.51-fold risk for AKI development during hospitalisation.
BACKGROUND: The risk of acute kidney injury (AKI) development among hospitalised patients with elevated calcium levels on admission remains unclear. The aim of this study was to assess the risk of AKI in hospitalised patients stratified by various admission serum calcium levels. METHODS: This is a single-centre retrospective study conducted at a tertiary referral hospital. All hospitalised adult patients who had admission calcium levels available between 2009 and 2013 were enrolled. Admission calcium was categorised based on its distribution into six groups (≤7.9, 8.0-8.4, 8.5-8.9, 9.0-9.4, 9.5-9.9, and ≥10.0 mg/dL). The primary outcome was hospital-acquired AKI. Logistic regression analysis was performed to obtain the odds ratio of AKI for various admission calcium strata using calcium levels of 8.0-8.4 mg/dL (lowest incidence of AKI) as the reference group. RESULTS: A total of 12 784 patients were studied. Hospital-acquired AKI occurred in 1779 (13.9%) patients. The incidence of AKI among patients with admission calcium ≤7.9, 8.0-8.4, 8.5-8.9, 9.0-9.4, 9.5-9.9 and ≥10 mg/dL was 14.7%, 11.7%, 11.8%, 14.6%, 15.8% and 17.3%, respectively. After adjusting for potential confounders, admission calcium levels ≤7.9, 9.0-9.4, 9.5-9.9 and ≥10 mg/dL were associated with increased risk of AKI with odds ratios of 1.36 (95%CI 1.08-1.72), 1.29 (95%CI 1.08-1.56), 1.38 (95%CI 1.14-1.68) and 1.51 (95%CI 1.19-1.91), respectively. CONCLUSION: Admission hypocalcaemia and hypercalcaemia are associated with an increased risk for hospital acquired AKI. Patients with admission hypercalcaemia (≥10 mg/dL) carry a 1.51-fold risk for AKI development during hospitalisation.
Authors: Wisit Cheungpasitporn; Charat Thongprayoon; Panupong Hansrivijit; Juan Medaura; Api Chewcharat; Tarun Bathini; Michael A Mao; Stephen B Erickson Journal: Adv Biomed Res Date: 2020-04-22
Authors: Joseph M Pappachan; Mohamed Nabil Elnaggar; Ravinder Sodi; Kahtan Jbeili; Paul R Smith; Ian M Lahart Journal: Endocrine Date: 2018-07-17 Impact factor: 3.633
Authors: Ibrahim Sandokji; Yu Yamamoto; Aditya Biswas; Tanima Arora; Ugochukwu Ugwuowo; Michael Simonov; Ishan Saran; Melissa Martin; Jeffrey M Testani; Sherry Mansour; Dennis G Moledina; Jason H Greenberg; F Perry Wilson Journal: J Am Soc Nephrol Date: 2020-05-07 Impact factor: 10.121
Authors: Charat Thongprayoon; Wisit Cheungpasitporn; Api Chewcharat; Michael A Mao; Kianoush B Kashani Journal: BMJ Open Date: 2020-03-23 Impact factor: 2.692
Authors: Charat Thongprayoon; Pradeep Vaitla; Voravech Nissaisorakarn; Michael A Mao; Jose L Zabala Genovez; Andrea G Kattah; Pattharawin Pattharanitima; Saraschandra Vallabhajosyula; Mira T Keddis; Fawad Qureshi; John J Dillon; Vesna D Garovic; Kianoush B Kashani; Wisit Cheungpasitporn Journal: Med Sci (Basel) Date: 2021-09-24